By Jeff Overley (January 4, 2013, 6:24 PM EST) -- The Massachusetts Institute of Technology on Friday hit Shire PLC with a patent infringement suit in Massachusetts federal court, alleging that the drugmaker's Dermagraft treatment for diabetic foot ulcers uses a protected method of growing cells to replace damaged skin.
The university's complaint centers on a patented polymer "scaffolding" that supports cell growth and is transferred into patients, where it helps patch wounds. According to MIT, Dermagraft uses cells that are derived from the foreskin of newborn babies and placed on a three-dimensional mesh scaffold, where they subsequently secrete collagen and generate substitute skin.
MIT and the nonprofit Children's Medical Center...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!